ACR Convergence 2025

October 24-29, 2025. Chicago, Illinois.

View by Number View by Title View Sessions

Tuesday, October 28, 2025

10:30AM-12:30PM: Abstract Number: 2018

Investigating Epidemiology, Clinical associations, and Outcomes of Uveitis: A Retrospective Cohort Study

(2015–2051) Miscellaneous Rheumatic & Inflammatory Diseases Poster III

10:30AM-12:30PM: Abstract Number: 1902

Investigating Factors Associated With Respiratory Syncytial Virus Vaccination and Breakthrough Infection Among Patients With Systemic Autoimmune Rheumatic Diseases

(1877–1913) Epidemiology & Public Health Poster III

10:30AM-12:30PM: Abstract Number: 2493

Investigating scoring systems to measure clinically relevant changes in systemic sclerosis-related finger acro-osteolysis over time, as assessed in serial hand radiographs

(2470–2503) Systemic Sclerosis & Related Disorders – Clinical Poster III

10:30AM-12:30PM: Abstract Number: 2483

Is There a Seasonal Variation in Raynaud’s Phenomenon Severity in Patients with Systemic Sclerosis?

(2470–2503) Systemic Sclerosis & Related Disorders – Clinical Poster III

10:30AM-12:30PM: Abstract Number: 2023

Isolated Anti-Ro52 Antibody Positivity Is Associated with Increased Cancer Risk and Distinct Malignancy Patterns: A Retrospective Cohort Study from a Single Tertiary Center

(2015–2051) Miscellaneous Rheumatic & Inflammatory Diseases Poster III

10:30AM-12:30PM: Abstract Number: 1960

Item Response Theory to Develop an Ultrasound Composite Score for Knee Osteoarthritis Assessment

(1936–1971) Imaging of Rheumatic Diseases Poster

10:30AM-12:30PM: Abstract Number: 2355

Ixekizumab Provided Rapid Improvement in Key Patient Subgroups with Psoriatic Arthritis: Findings from a Prospective Observational Study in the United States of Patients Initiating Ixekizumab or Interleukin-23 Inhibitors

(2338–2376) Spondyloarthritis Including Psoriatic Arthritis – Treatment Poster III

10:30AM-12:30PM: Abstract Number: 2375

Ixekizumab Provided Rapid Improvements in Quality of Life and Disease Activity in Patients with Psoriatic Arthritis: Findings from a Real-World Study in the United States of Patients Initiating Ixekizumab or Interleukin-23 Inhibitors

(2338–2376) Spondyloarthritis Including Psoriatic Arthritis – Treatment Poster III

10:30AM-12:30PM: Abstract Number: 2036

JAK1 selective inhibitors versus pan-JAK inhibitors: comparative real-world study of drug retention in chronic inflammatory arthritis

(2015–2051) Miscellaneous Rheumatic & Inflammatory Diseases Poster III

10:30AM-12:30PM: Abstract Number: 2339

Joint Groups Involved in Early Oligoarticular Psoriatic Arthritis and the Impact of Apremilast Treatment: Data From FOREMOST

(2338–2376) Spondyloarthritis Including Psoriatic Arthritis – Treatment Poster III

10:30AM-12:30PM: Abstract Number: 2269

Key factors in optimizing the dose of Baricitinib in rheumatoid arthritis: a study based on routine clinical practice and its therapeutic implications

(2265–2289) Rheumatoid Arthritis – Treatment Poster III

10:30AM-12:30PM: Abstract Number: 2427

Kidney-Specific Four-Protein Index Outperforms Conventional Measures for Detecting Early Kidney Damage in Lupus Nephritis and Diabetic Kidney Disease

(2377–2436) Systemic Lupus Erythematosus – Diagnosis, Manifestations, & Outcomes Poster III

10:30AM-12:30PM: Abstract Number: 2064

Kinematics Underlying IBM-induced Dysphagia

(2052–2078) Muscle Biology, Myositis & Myopathies – Basic & Clinical Science Poster III

10:30AM-12:30PM: Abstract Number: 2171

Knowledge of Fertility and Infertility Treatments Among Physicians Treating Women with Rheumatic Diseases: FIT-KS Survey

(2159–2194) Professional Education Poster

10:30AM-12:30PM: Abstract Number: 2030

Krebs von den Lungen 6 levels (∆KL6) is a reliable marker of disease activity and response to therapy in CTD-ILD

(2015–2051) Miscellaneous Rheumatic & Inflammatory Diseases Poster III

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].